A detailed history of Jpmorgan Chase & CO transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 90,426 shares of LXRX stock, worth $109,415. This represents 0.0% of its overall portfolio holdings.

Number of Shares
90,426
Previous 90,136 0.32%
Holding current value
$109,415
Previous $216,000 30.09%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$1.54 - $2.28 $446 - $661
290 Added 0.32%
90,426 $151,000
Q1 2024

May 10, 2024

SELL
$1.3 - $3.58 $3.84 Million - $10.6 Million
-2,953,155 Reduced 97.04%
90,136 $216,000
Q4 2023

Feb 12, 2024

BUY
$1.0 - $1.53 $228,257 - $349,233
228,257 Added 8.11%
3,043,291 $4.66 Million
Q3 2023

Nov 14, 2023

SELL
$1.06 - $2.33 $123,103 - $270,594
-116,135 Reduced 3.96%
2,815,034 $3.07 Million
Q2 2023

Aug 11, 2023

SELL
$2.15 - $3.49 $805,867 - $1.31 Million
-374,822 Reduced 11.34%
2,931,169 $6.71 Million
Q1 2023

May 18, 2023

BUY
$1.99 - $2.68 $126,952 - $170,970
63,795 Added 1.97%
3,305,991 $8.03 Million
Q1 2023

May 11, 2023

SELL
$1.99 - $2.68 $68,857 - $92,733
-34,602 Reduced 1.06%
3,242,196 $7.88 Million
Q4 2022

Feb 13, 2023

BUY
$1.8 - $2.56 $90,657 - $128,934
50,365 Added 1.56%
3,276,798 $6.26 Million
Q3 2022

Nov 14, 2022

BUY
$1.94 - $3.43 $4.06 Million - $7.18 Million
2,093,656 Added 184.83%
3,226,433 $7.74 Million
Q2 2022

Aug 11, 2022

BUY
$1.31 - $2.69 $4,527 - $9,296
3,456 Added 0.31%
1,132,777 $2.11 Million
Q1 2022

May 11, 2022

SELL
$1.95 - $3.89 $36,599 - $73,011
-18,769 Reduced 1.63%
1,129,321 $2.36 Million
Q4 2021

Feb 10, 2022

SELL
$3.81 - $6.16 $36,625 - $59,216
-9,613 Reduced 0.83%
1,148,090 $4.52 Million
Q3 2021

Nov 12, 2021

BUY
$3.38 - $5.35 $3.91 Million - $6.19 Million
1,157,703 New
1,157,703 $5.57 Million

Others Institutions Holding LXRX

About LEXICON PHARMACEUTICALS, INC.


  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $228M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.